Nathaniel Youndt is the Vice President of Business Strategy and Program Management for ReciBioPharm (a Division of Recipharm AB), pursuing strategic partnerships and opportunities that position ReciBioPharm as a leading CDMO in nucleic acid, viral, and microbiome spaces. With a mission to deliver for customers with credibility and integrity every day, Nathaniel's experience spans clinical and commercial CDMO spaces, holding roles of progressive responsibility at AMRI (now Curia), Thermo Fisher Scientific (Patheon), and Arranta Bio, prior to its acquisition by Recipharm. From small molecule pharmaceuticals to biologics and ATMPs, Nathaniel held responsibility for programs across mRNA, peptides, lipid nanoparticles and liposomes, plasmid DNA, live biotherapeutics, and viral vectors. He holds a BA from Gordon College and an MBA from Indiana Wesleyan University.